In short
Clinical trials investigating Salbutamol Sulfate are studying how it is used in different patient groups, including people with asthma, COPD, bronchiectasis, newborn breathing problems, hyperkalemia, and ALS. These trials mainly look at safety, tolerability, and treatment effects, with endpoints such as lung function, exacerbations, mortality, potassium levels, and walking capacity.
Key points
- Clinical trials investigating Salbutamol Sulfate focus on several patient groups, especially people with asthma and COPD. Other studies include bronchiectasis, newborn breathing disorders, hyperkalemia, episodic wheezing in young children, and ALS. The trials are mostly Phase 2 and Phase 3, with one low-intervention study and one Phase 1 study. Main outcomes include safety, tolerability, lung function, exacerbation rates, mortality, potassium change, symptom control, and walking ability. Some studies are completed, while others are ongoing or authorised.
Trial overview
These studies investigate Salbutamol Sulfate in different clinical settings, mostly as part of larger interventional trials. The trial data show research in asthma, COPD, bronchiectasis, newborn breathing disorders, hyperkalemia, and ALS.
Conditions studied
Asthma is one of the main conditions studied, including adult asthma, severe eosinophilic asthma, T2-high asthma, and asthma in children with episodic wheezing. COPD is another major area, including symptomatic COPD, COPD with a history of exacerbations, acute exacerbation of COPD, and COPD with type 2 inflammation. Other trials study bronchiectasis, cystic fibrosis bronchiectasis, neonatal respiratory failure linked to pulmonary hypertension, hyperkalemia, and ALS.
Trial phases and status
Most of the trials are Phase 2 or Phase 3, which means they are testing how well the study approach works and how safe it is in larger groups of people. One study is listed as Phase 1 and focuses on safety and tolerability in non-cystic fibrosis bronchiectasis. Some studies are completed, some are authorised, one is ongoing, and several were withdrawn before completion.
Main endpoints and what they mean
Several trials measure treatment-emergent adverse events, which are health problems that begin or worsen after treatment starts. Lung studies often use FEV1, a test of how much air a person can blow out in one second, and some use FEV1 over time after treatment. Other endpoints include annualized exacerbation rates, 30-day mortality, serum potassium change at 60 minutes, symptom control, and the 6-minute walking test.
Who participates in these trials
Participants include adults with asthma or COPD, children aged 1 to 6 years with episodic wheezing, adolescents and adults with severe eosinophilic asthma, newborns with breathing disorders, and ambulatory ALS patients. Some studies also focus on former smokers with COPD.
Study designs and comparators
Most trials are interventional, meaning the researchers assign treatments and compare outcomes between groups. Several studies compare Salbutamol Sulfate with placebo, while others compare it with active treatments or use it as part of standard care. In some studies, Salbutamol Sulfate is used together with another treatment, so the study is really testing the full treatment plan rather than Salbutamol Sulfate alone.
Patient-focused summary
For patients, the main point is that Salbutamol Sulfate is being studied in many different groups, not just one disease. The research is looking at both safety and how well the treatment plan works in real clinical situations. The outcomes are practical ones that matter to patients, such as breathing ability, flare-ups, emergency events, daily function, and short-term survival in some settings.